We are doing a study to see if a new treatment, called INO-3107, can help people with recurrent respiratory papillomatosis (RRP). We want to find out if this treatment works well and if it helps patients need fewer surgeries in the future.

Do you have incurable, metastatic head and neck squamous cell carcinoma ? If so, you may be able to take part in a study to see if a new drug called Cisplatin is effective.

Do you have acid reflux, GERD, or Barrett's Esophagus? Are you having standard of care endoscopies performed? You may be able to participate in a research study testing for Barrett's Esophagus and esophageal cancer. Compensation provided.

Have you diagnosed with lymph node positive early breast cancer, have received surgery, and have not received any systemic or radiation treatment prior to surgery? If so, you may be able to take part in this clinical trial which seeks to improve the treatment of early-stage breast cancer by examining ctDNA, a biomarker found in the blood that may indicate the presence of disease. This study aims to determine if ctDNA can help doctors personalize therapies leading to more effective treatment plans.

Have you been diagnosed with Leukemia? Do you have a functioning kidney, liver, and cardiac organ? If so, you may be able to participate in a study on a new drug called LBS-007. We want to find out if it is safe for people with Leukemia. Compensation provided.

The purpose of this study is to determine if epcoritamab can be used to treat patients with previously treated WM.

The purpose of this study is to determine whether a new investigational combination of drugs, that contains belantamab mafodotin with belantamab, will be as effective, and more tolerable, compared to belantamab mafodotin alone in participants with multiple myeloma that has become active again after at least three prior lines of treatment.

To determine the anti-proliferative effect of tirzepatide on the endometrium of endometrial cancer (EC) patients .

This trial seeks to enroll patients diagnosed with HER2-negative (HER2- low or HER2-0)- MBC who are starting treatment with T-DXd. The purpose is to determine if the test used for HER2+ MBC also works for HER2-low MBC. By participating in this trial, you are contributing to information that may improve the care of future patients with HER2-negative (HER2- low or HER2-0)- MBC. This trial does not require additional biopsies. Only tissue left over from a standard-of-care procedure will be used. The study team will access your medical record to review routine imaging test results as well as track your response to your treatment. Your breast cancer care will be managed by your oncologist, and you won't need to interact with the study team for direct care. No extra visits with the study team are required, except possibly for the initial enrollment.

The purpose of this study is to find the maximum tolerated dose and the recommended Phase 2 dose of IOV-3001 infusion given after lifileucel to participants with advanced (unresectable or metastatic) melanoma who meet the requirements for treatment with lifileucel. The study duration for each participant will be up to about 6 months (Phase 1, Part 1) or 5 years (Phase 1, Part 2) after the lifileucel dose. Study intervention begins with surgery to get a tumor sample that will be used to make lifileucel